MiR-182 shows oncogenic features by promoting growth in oral squamous cell carcinoma, hepatocellular carcinoma, gastric cancer cells, and bladder cancer cells through repressing CAMK2N1, FOXO3a, RAB27A, Smad4, or RECK, while miR-182 plays a role as a tumor suppressor in renal cell carcinoma, Ewing’s sarcoma, and fibromatosis [27,28,29,30,31]. Here, SMAD4 is linked to urinary bladder cancer.